Global Heart Tumor Market 2023-2029

March 2023 | 64 pages | ID: G5C655B1ED3BEN
Gen Consulting Company

Abstracts

The global heart tumor market was valued at USD 830.0 million in 2022 to USD 1,267.0 million by 2029, progressing at a CAGR of 6.3% from 2023 to 2029, according to the latest market study results. A heart tumor is a rare type of tumor that grows in or around the heart. Heart tumors can be either benign (non-cancerous) or malignant (cancerous). Benign heart tumors are more common than malignant heart tumors. The most common types of benign heart tumors are myxomas, which grow in the heart's lining and can cause symptoms such as shortness of breath, chest pain, and heart palpitations. Malignant heart tumors are rare and can be either primary tumors, which originate in the heart, or secondary tumors, which spread from other parts of the body. The symptoms of malignant heart tumors can vary depending on the location and type of tumor, but may include chest pain, shortness of breath, irregular heartbeat, and fatigue. Treatment for heart tumors may include surgery, radiation therapy, chemotherapy, or a combination of these therapies.A heart tumor is a rare type of tumor that grows in or around the heart. Heart tumors can be either benign (non-cancerous) or malignant (cancerous). Benign heart tumors are more common than malignant heart tumors. The most common types of benign heart tumors are myxomas, which grow in the heart's lining and can cause symptoms such as shortness of breath, chest pain, and heart palpitations. Malignant heart tumors are rare and can be either primary tumors, which originate in the heart, or secondary tumors, which spread from other parts of the body. The symptoms of malignant heart tumors can vary depending on the location and type of tumor, but may include chest pain, shortness of breath, irregular heartbeat, and fatigue. Treatment for heart tumors may include surgery, radiation therapy, chemotherapy, or a combination of these therapies.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global heart tumor market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the tumor type, type, and region. The global market for heart tumor can be segmented by tumor type: primary tumor, secondary tumor. Globally, the secondary tumor segment made up the largest share of the heart tumor market. Heart tumor market is further segmented by type: diagnosis, treatment. The treatment segment captured the largest share of the market in 2022. Based on region, the heart tumor market is segmented into: North America, Europe, Asia-Pacific, Rest of the World (RoW). According to the research, North America had the largest share in the global heart tumor market.

The diagnosis market is further segmented into CT scan, MRI scan, nuclear imaging, electrophysiology test, others. The electrophysiology test segment was the largest contributor to the global heart tumor market in 2022. Furthermore, the treatment market has been categorized into surgery, chemotherapy, radiotherapy, others. The surgery segment is estimated to account for the largest share of the global heart tumor market.

Market Segmentation
By tumor type: primary tumor, secondary tumor
By type: diagnosis, treatment
By region: North America, Europe, Asia-Pacific, Rest of the World (RoW)

The global heart tumor market report offers detailed information on several market vendors, including Koninklijke Philips N.V., GE Healthcare, Siemens AG, Boston Scientific Corporation, Toshiba Corporation, Shimadzu Corporation, Terumo Corporation, Fujifilm Corporation, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global heart tumor market.
To classify and forecast the global heart tumor market based on tumor type, type, region.
To identify drivers and challenges for the global heart tumor market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global heart tumor market.
To identify and analyze the profile of leading players operating in the global heart tumor market.

Why Choose This Report
Gain a reliable outlook of the global heart tumor market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY TUMOR TYPE

Primary tumor
Secondary tumor

PART 6. MARKET BREAKDOWN BY TYPE

Diagnosis
Treatment

PART 7. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
Rest of the World (RoW)

PART 8. KEY COMPANIES

Koninklijke Philips N.V.
GE Healthcare
Siemens AG
Boston Scientific Corporation
Toshiba Corporation
Shimadzu Corporation
Terumo Corporation
Fujifilm Corporation

DISCLAIMER